| Heart disease and stroke statistics—2013 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, WB Borden, ... circulation 127 (1), e6-e245, 2013 | 77508* | 2013 |
| Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study MJ O'donnell, D Xavier, L Liu, H Zhang, SL Chin, P Rao-Melacini, ... The Lancet 376 (9735), 112-123, 2010 | 4558 | 2010 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2644 | 2019 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2605 | 2017 |
| Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries CK Chow, KK Teo, S Rangarajan, S Islam, R Gupta, A Avezum, ... Jama 310 (9), 959-968, 2013 | 2589* | 2013 |
| Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study MJ O'Donnell, SL Chin, S Rangarajan, D Xavier, L Liu, H Zhang, ... The lancet 388 (10046), 761-775, 2016 | 2421 | 2016 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2217* | 2021 |
| Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study DP Leong, KK Teo, S Rangarajan, P Lopez-Jaramillo, A Avezum, ... The lancet 386 (9990), 266-273, 2015 | 1979 | 2015 |
| Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort … S Yusuf, P Joseph, S Rangarajan, S Islam, A Mente, P Hystad, M Brauer, ... The Lancet 395 (10226), 795-808, 2020 | 1745 | 2020 |
| The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study SA Lear, W Hu, S Rangarajan, D Gasevic, D Leong, R Iqbal, A Casanova, ... The Lancet 390 (10113), 2643-2654, 2017 | 1479 | 2017 |
| Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study M Dehghan, A Mente, X Zhang, S Swaminathan, W Li, V Mohan, R Iqbal, ... The Lancet 390 (10107), 2050-2062, 2017 | 1285 | 2017 |
| Cardiovascular risk and events in 17 low-, middle-, and high-income countries S Yusuf, S Rangarajan, K Teo, S Islam, W Li, L Liu, J Bo, Q Lou, F Lu, ... New England Journal of Medicine 371 (9), 818-827, 2014 | 1167 | 2014 |
| Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective … S Yusuf, S Islam, CK Chow, S Rangarajan, G Dagenais, R Diaz, R Gupta, ... The Lancet 378 (9798), 1231-1243, 2011 | 1114 | 2011 |
| Urinary sodium and potassium excretion, mortality, and cardiovascular events M O'Donnell, A Mente, S Rangarajan, MJ McQueen, X Wang, L Liu, H Yan, ... New England Journal of Medicine 371 (7), 612-623, 2014 | 1093 | 2014 |
| Cholesterol lowering in intermediate-risk persons without cardiovascular disease S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ... New England Journal of Medicine 374 (21), 2021-2031, 2016 | 1068 | 2016 |
| Association of urinary sodium and potassium excretion with blood pressure A Mente, MJ O'Donnell, S Rangarajan, MJ McQueen, P Poirier, ... New england journal of medicine 371 (7), 601-611, 2014 | 1034 | 2014 |
| A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ... The Lancet 388 (10060), 2665-2712, 2016 | 1007 | 2016 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 995 | 2018 |
| Blood-pressure lowering in intermediate-risk persons without cardiovascular disease EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ... New England Journal of Medicine 374 (21), 2009-2020, 2016 | 824 | 2016 |
| Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study GR Dagenais, DP Leong, S Rangarajan, F Lanas, P Lopez-Jaramillo, ... The Lancet 395 (10226), 785-794, 2020 | 727 | 2020 |
Salim YusufPopulation Health Research Institute, McMaster University and Hamilton Health SciencesVerified email at mcmaster.ca
